BridgeMD
New treatment option for Stroke, Ischemic
Official title Effect of Supplementation With Creatine on the Recovery of Ischemic Stroke
ClinicalTrials.gov ID: NCT06576466
What this study is testing
- What it's testing
- Stroke is a leading cause of disability and the second leading cause of death worldwide. Most strokes are ischemic, caused by acute arterial occlusion.
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Age between 18 and 80 years
- Recent diagnosis of ischemic stroke (from 24 hours to 5 days) .
- Neurological deficit due to the stroke that affects mobility (paresis and/or ataxia) and requires motor rehabilitation.
- Ability to understand and sign the informed consent form, or failing that, have sufficient support to carry out the correct follow-up of the study.
You likely can't join if
- Moderate-severe disability prior to stroke, defined by an mRS\>2.
- Unstable or severe clinical situation that prevents active rehabilitation.
- Neurological deficit due to stroke that prevents walking without help from another person. The use of support with a cane, crutch or walker is...
- Moderate or severe dysphagia that makes therapeutic adherence difficult.
- Use of creatine supplements in the last 3 months, or use of anabolic products in the last 3 months.
- Severe kidney disease (GFR \<30ml/min/1.73 m2).
See the full eligibility criteria
- Age between 18 and 80 years
- Recent diagnosis of ischemic stroke (from 24 hours to 5 days) .
- Neurological deficit due to the stroke that affects mobility (paresis and/or ataxia) and requires motor rehabilitation.
- Ability to understand and sign the informed consent form, or failing that, have sufficient support to carry out the correct follow-up of the study.
- Moderate-severe disability prior to stroke, defined by an mRS\>2.
- Unstable or severe clinical situation that prevents active rehabilitation.
- Neurological deficit due to stroke that prevents walking without help from another person. The use of support with a cane, crutch or walker is permitted.
- Moderate or severe dysphagia that makes therapeutic adherence difficult.
- Use of creatine supplements in the last 3 months, or use of anabolic products in the last 3 months.
- Severe kidney disease (GFR \<30ml/min/1.73 m2).
- Musculoskeletal pathology that prevents assessment of muscle strength. For example: fractures, severe osteoarthritis, ligament tears or tendinopathies.
- History of allergic reactions to creatine.
- Pregnancy or breastfeeding.
- Simultaneous participation in another clinical trial.
The study team makes the final eligibility decision.
Where it's taking place
- Palma de Mallorca, Balearic Islands, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Palma de Mallorca, Balearic Islands, Spain. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.